Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)
Latest Information Update: 07 May 2024
At a glance
- Drugs AKS-452 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms ACT-BOOSTER Study
- 26 Feb 2024 Results published in an Akston Biosciences media release.
- 26 Feb 2024 According to an Akston Biosciences media release, announced the publication of phase II study results in Nature Vaccines.
- 01 Nov 2022 According to an Akston Biosciences media release, interim data from this study support a Phase III universal booster study for AKS-452